Direct Funding
Action to Cure Kidney Cancer has directly funded kidney cancer research since 2006 and has provided 22 grants to 10 researchers totaling $427,282.50. The following details specific information about each grant by year, identifying the researcher, his or her institution, the purpose of the grant and the amount paid. The grants cover a broad spectrum of research from attempting to develop an early screening test for kidney cancer to working to find treatments for the different types of kidney cancer.
Kidney Cancer Research Projects
Role of Ketogenesis in Preventing RCC-Associated Cachexia
2018 — $30,000Sarah Huen
University of Texas Southwestern
Project: Test the hypothesis that ketones are required to protect against the development of cachexia in RCC, which contributes to at least 20% of cancer-related mortality.
Therapies for Papillary Renal Cell Carcinoma
2014 to 2016 — $60,000Marston Linehan
National Cancer Institute
Project: Non-clear cell research, specifically therapies for papillary renal cell carcinoma.
Role of Gene SETD2 in Development of Kidney Cancer
2012 — $45,000Eric Jonasch
MD Anderson Cancer Center
Project: Examine consequences of the loss of the gene SETD2 and the formation of kidney cancer.
Kidney Cancer Clinical Work and Research Studies
2011 — $10,000Janice Dutcher
St. Lukes Roosevelt Hospital
Project: Support her kidney cancer clinical and research work at Roosevelt Hospital in New York City.
Radiological Treatment for Metastic Kidney Cancer
2010 — $30,000Denise Chan
University of California, San Francisco
Project: Study the efficacy of radiological treatment for metastic kidney cancer.
Prevention of Glucose Uptake in VHL-Mutated Cells
2009 — $45,000Amato Giaccia
Stanford University
Project: Support the study of a protein that prevents glucose uptake in VHL-mutated cells and thereby, via synthetic lethality, destroys the kidney cancer cells.
Identification of Human Endogenous Retrovirus (HERV)
2009, 2008, 2007, 2006 — $35,600, 55,600, 20,000, 35,000 respectively, for a total of $146,200Richard Childs
National Institutes of Health
Project: Support the identification of a human endogenous retrovirus (HERV) that is selectively expressed on 80 percent of renal cell carcinoma cells.
Analysis of Polymearse Chain Reaction (PCR)
2006 — $44,782.50Paul Cairns
Fox Chase Cancer Center
Project: Purchase a Polymearse Chain Reaction (PCR) machine to analyze DNA in order to develop a urine test that would detect early stage kidney cancer.
